Matt Miksic
Stock Analyst at Barclays
(3.97)
# 595
Out of 5,090 analysts
307
Total ratings
61.09%
Success rate
7%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $176 → $197 | $202.48 | -2.71% | 14 | Dec 2, 2025 | |
| MDT Medtronic | Maintains: Overweight | $109 → $111 | $101.99 | +8.83% | 22 | Nov 20, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $12 → $11 | $4.71 | +133.55% | 3 | Nov 12, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $51 → $55 | $20.65 | +166.34% | 8 | Nov 10, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $106 → $114 | $88.74 | +28.47% | 16 | Nov 10, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $301 → $316 | $316.45 | -0.14% | 11 | Nov 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $105 → $104 | $93.16 | +11.64% | 9 | Nov 6, 2025 | |
| SENS Senseonics Holdings | Maintains: Overweight | $1.5 → $31 | $6.74 | +359.94% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $98 → $80 | $65.27 | +22.57% | 8 | Nov 3, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $22 → $23 | $21.23 | +8.36% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $99 | $85.78 | +15.41% | 30 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.81 | +1.13% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $364.35 | +24.33% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $159 → $162 | $125.40 | +29.19% | 30 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $82.46 | +4.30% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $85 | $77.30 | +9.96% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $78.99 | +8.87% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $136 | $97.72 | +39.17% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.30 | +169.23% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $58 | $63.67 | -8.91% | 8 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $18.48 | +94.81% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.34 | +46.44% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $193.76 | +24.38% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $568.65 | +11.67% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.55 | +383.52% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $73.13 | +36.74% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $156.38 | +167.30% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.50 | +69.75% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.27 | +494.76% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $3.00 | +15,900.00% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $13.55 | +541.92% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.90 | +410.73% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.82 | +32.06% | 1 | Dec 12, 2016 |
Johnson & Johnson
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $176 → $197
Current: $202.48
Upside: -2.71%
Medtronic
Nov 20, 2025
Maintains: Overweight
Price Target: $109 → $111
Current: $101.99
Upside: +8.83%
Orchestra BioMed Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.71
Upside: +133.55%
Tandem Diabetes Care
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $20.65
Upside: +166.34%
Globus Medical
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $88.74
Upside: +28.47%
Insulet
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $301 → $316
Current: $316.45
Upside: -0.14%
Zimmer Biomet Holdings
Nov 6, 2025
Maintains: Underweight
Price Target: $105 → $104
Current: $93.16
Upside: +11.64%
Senseonics Holdings
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.74
Upside: +359.94%
DexCom
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $80
Current: $65.27
Upside: +22.57%
Alphatec Holdings
Nov 3, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $21.23
Upside: +8.36%
Oct 31, 2025
Maintains: Overweight
Price Target: $95 → $99
Current: $85.78
Upside: +15.41%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.81
Upside: +1.13%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $364.35
Upside: +24.33%
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $125.40
Upside: +29.19%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $82.46
Upside: +4.30%
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $77.30
Upside: +9.96%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $78.99
Upside: +8.87%
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $97.72
Upside: +39.17%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.30
Upside: +169.23%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $63.67
Upside: -8.91%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $18.48
Upside: +94.81%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.34
Upside: +46.44%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $193.76
Upside: +24.38%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $568.65
Upside: +11.67%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.55
Upside: +383.52%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $73.13
Upside: +36.74%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $156.38
Upside: +167.30%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.50
Upside: +69.75%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.27
Upside: +494.76%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $3.00
Upside: +15,900.00%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $13.55
Upside: +541.92%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.90
Upside: +410.73%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.82
Upside: +32.06%